CDKN2A and cancer: These results provide evidence that ERE73 (1 + 2)-ARF (−13) and ERE73 (3 + 4)-ARF (−13) are promising promoter constructs to selectively drive cytotoxic gene expression in cancer cells, leading to cancer cell-specific killing in vitro.